Reevaluation of a Bicyclic Pyrazoline as a Selective 15-Lipoxygenase V-Type Activator Possessing Fatty Acid Specificity.

Regulation of lipoxygenase (LOX) activity is of great interest due to the involvement of the various LOX isoforms in the inflammatory process and hence many diseases. The bulk of investigations have centered around the discovery and design of inhibitors. However, the emerging understanding of the role of h15-LOX-1 in the resolution of inflammation provides a rationale for the development of activators as well. Bicyclic pyrazolines are known bioactive molecules that have been shown to display antibiotic and anti-inflammatory activities. In the current work, we reevaluated a previously discovered bicyclic pyrazoline h15-LOX-1 activator, PKUMDL_MH_1001 (written as for this publication), and determined that it is inactive against other human LOX isozymes, h5-LOX, h12-LOX, and h15-LOX-2. Analytical characterization of obtained in the final synthesis step identified it as a mixture of - and diastereomers: - (12%) and - (88%); and kinetic analysis indicated similar potency between the two. Using compound as the - mixture, h15-LOX-1 catalysis with arachidonic acid (AA) (AC = 7.8 +/- 1 μM, = 240%) and linoleic acid (AC = 5.3 +/- 0.7 μM, = 98%) was activated, but not with docosahexaenoic acid (DHA) or mono-oxylipins. Steady-state kinetics demonstrate V-type activation for , with a β value of 2.2 +/- 0.4 and an of 16 +/- 1 μM. Finally, it is demonstrated that the mechanism of activation for is likely not due to decreasing substrate inhibition, as was postulated previously. also did not affect the activity of the h15-LOX-1 selective inhibitor, ML351, nor did affect the activity of allosteric effectors, such as 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12S-HETE) and 14S-hydroperoxy-4,7,10,12,16,19-docosahexaenoic acid (14S-HpDHA). These data confirm that binds to a distinct activation binding site, as previously postulated. Future work should be aimed at the development of selective activators that are capable of activating h15-LOX-1 catalysis with DHA, thus enhancing the production of DHA-derived pro-resolution biomolecules.